Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils by Pye, R. et al.




Ruth Pye, Rodrigo Hamede, Hannah V. Siddle, Alison Caldwell, Graeme W. Knowles, Kate Swift, 
Alexandre Kreiss, Menna E. Jones, A. Bruce Lyons, Gregory M. Woods 
Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils 
Biology Letters, 2016; 12(10):20160553-1-20160553-5 
© 2016 The Authors. Published by the Royal Society under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, 
provided the original author and source are credited. 























       
 
27 June 2017 
 
 on June 26, 2017http://rsbl.royalsocietypublishing.org/Downloaded from rsbl.royalsocietypublishing.orgResearch
Cite this article: Pye R et al. 2016
Demonstration of immune responses against
devil facial tumour disease in wild Tasmanian
devils. Biol. Lett. 12: 20160553.
http://dx.doi.org/10.1098/rsbl.2016.0553Received: 29 June 2016
Accepted: 22 September 2016Subject Areas:
ecology, health and disease and epidemiology
Keywords:
Tasmanian devil, devil facial tumour disease,
immune response, transmissible cancer,




e-mail: g.m.woods@utas.edu.auElectronic supplementary material is available
online at https://dx.doi.org/10.6084/m9.fig-
share.c.3500358.
& 2016 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.Conservation biology
Demonstration of immune responses
against devil facial tumour disease in
wild Tasmanian devils
Ruth Pye1, Rodrigo Hamede3, Hannah V. Siddle4, Alison Caldwell4,
Graeme W. Knowles5, Kate Swift5, Alexandre Kreiss1, Menna E. Jones3,
A. Bruce Lyons2 and Gregory M. Woods1,2
1Menzies Institute for Medical Research, and 2School of Medicine, University of Tasmania, Hobart,
Tasmania 7000, Australia
3School of Biological Sciences, University of Tasmania, Hobart, Tasmania 7001, Australia
4Centre for Biological Science, University of Southampton, Highfield Campus, Southampton SO17 1BJ, UK
5Department of Primary Industries, Parks, Water and Environment, Hobart, Tasmania 7000, Australia
GMW, 0000-0001-8421-7917
Devil facial tumour disease (DFTD) is a recently emerged fatal transmissible
cancer decimating the wild population of Tasmanian devils (Sarcophilus har-
risii). Biting transmits the cancer cells and the tumour develops in the new
host as an allograft. The literature reports that immune escape mechanisms
employed by DFTD inevitably result in host death. Here we present the first
evidence that DFTD regression can occur and that wild devils can mount an
immune response against the disease. Of the 52 devils tested, six had serum
antibodies against DFTD cells and, in one case, prominent T lymphocyte
infiltration in its tumour. Notably, four of the six devils with serum antibody
had histories of DFTD regression. The novel demonstration of an immune
response against DFTD in wild Tasmanian devils suggests that a proportion
of wild devils can produce a protective immune response against naturally
acquired DFTD. This has implications for tumour–host coevolution and
vaccine development.1. Introduction
The Tasmanian devil is the world’s largest carnivorous marsupial and unique
to Tasmania, the island state of Australia. The species is listed as Endangered
owing to mortality from devil facial tumour disease (DFTD) [1]. The disease
is a transmissible cancer, first observed in 1996 in the far northeast of the
state. It is now found throughout the majority of the devil’s geographical
range [2]. DFTD is transmitted when susceptible and infected individuals bite
each other and is considered invariably fatal, with most animals dying within
6–12 months of the tumour first appearing [3].
In 2015, a second transmissible facial cancer was reported in Tasmanian
devils in the southeast of the state [4]. This second cancer was named DFT2,
and in the report the original cancer was termed DFT1, with DFTD denoting
both. This paper follows the nomenclature and refers to DFT1. The disease is
transmitted as an allograft [5] and three explanations were initially suggested
to explain the lack of immune rejection: the limited genetic diversity of the
species; the unknown competency of the devil’s immune system; and the
immune evasion mechanisms of the tumour [2]. All research to date addressing
these possibilities suggests that it is the successful immune evasion strategies
Table 1. DFTD and antibody (Ab) status of six Tasmanian devils exhibiting anti-DFT1 responses. Serum Ab column: ‘/’, no serum sample collected; ‘negative’,
same as MFI control; ‘medium’, 2–4 MFI control; and ‘high’, .4 MFI control. YOB, year of birth; FNA, ﬁne needle aspirate.
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for transmission of DFT1 [2,6,7].
Current DFT1 research suggests that a major mechanism
of immune escape is downregulation of the major histocom-
patibility complex class I molecule (MHC-I) [7]. MHC-I cell
surface expression occurs on all nucleated cells and allows
the immune system to recognize foreign or infected cells.
Some cancers fail to express surface MHC-I, a mechanism
that contributes to evasion of the host’s T cell response. The
only other naturally occurring transmissible cancer to affect
a mammalian species is canine transmissible venereal
tumour (CTVT) in domestic dogs. CTVT also adopts MHC-
I downregulation in its progressive phase [8]. However,
after three to four months of tumour growth, there is
increased surface MHC-I expression resulting in a host allo-
response. This is demonstrated by host antibody production
and T lymphocyte infiltration of the tumour resulting in
tumour stabilization or regression and immunological
memory. MHC-I expression is associated with the presence
of inflammatory cytokines [8,9]. Likewise, DFT1s downregu-
lation of surface MHC-I can be reversed in vitro by treatment
of DFT1 cells with the inflammatory cytokine interferon
gamma (IFN-g) [7].
Downregulation of MHC-I provides an explanation for
DFT1 transmission and is believed to be responsible for the
lack of a T-cell-mediated immune response against the
tumour. The long-standing assumptions are that DFT1
always escapes the devil’s immune system, and that the
disease is invariably fatal. We re-examined these assumptions
by analysing serum and tumour samples from a population ofwild devils to detect the presence of anti-DFT1 immune
responses.2. Material and methods
Serum samples collected from 52 devils between 2008 and 2014
from a closely monitored population in northwestern Tasmania
were evaluated for the presence of IgG antibodies against
DFT1 cells. This was done via indirect immunofluorescence
and flow cytometry with the median fluorescence intensity
(MFI) of each sample recorded [10]. For 45 of the individual
devils, multiple serum samples collected over an extended
period were analysed. Serum samples were tested against
DFT1 cells not expressing MHC-I, referred to as MHC-I2ve
DFT1 cells, and separately against DFT1 cells treated with
IFN-g to induce cell surface expression of MHC-I [7], referred
to here as MHC-Iþve DFT1 cells. Sera from a translocated popu-
lation of captive born devils living in wild conditions on a
DFTD-free island were used as the negative control.
Of the 52 devils, 34 either had DFT1 at the start or
developed DFT1 during the course of sampling. Where
tumour biopsies were available, histopathological examin-
ation included identification of tumour-infiltrating immune
cells. Immunohistochemistry using anti-MHC-II antibody to
identify antigen-presenting cells and anti-CD3 antibody to
identify T lymphocytes in the biopsy was performed where
indicated [11]. Where immunocytochemistry (ICC) was per-
formed on tumour fine needle aspirates (FNAs), the samples
were stained for periaxin, a positive marker for DFT1 cells
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Figure 1. Flow cytometric analysis of anti-DFT1 antibody responses. (a)– ( f ) IgG serum antibody results of TD1–6 against MHC-Iþve DFT1 cells compared with
negative control. In brackets are the dates each devil was first observed with DFT1 (Dþ) and when the tumour was no longer present (D2); (g) representative
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collection, and analyses are provided in the electronic
supplementary material.3. Results
Of the 52 devils, 46 had no detectable serum IgG antibody
against either MHC-Iþve or MHC-I2ve DFT1 cells. The
remaining six devils (referred to here as TD1–6) had
serum IgG antibody against MHC-Iþve DFT1 cells, but not
MHC-I–ve cells. None of these six devils had clinical signs
of DFT1 at initial sample collection, but developed DFT1 at
some stage during sample collection (table 1).
Multiple serum samples from each of the six devils were
analysed and for each devil the earliest sample had the same
MFI as the negative control. After these devils showed clinical
signs of DFT1, they developed anti-DFT1 antibodies
(figure 1). Remarkably, DFT1 regression occurred in four of
the six devils that had seroconverted (TD1, TD2, TD3 and
TD4). When each devil was retrapped between four and 15
months after DFT1 was first noted, their tumours were no
longer visible and anti-DFT1 antibodies were detected. TD1
and TD2 were not retrapped after the regression was
observed. TD3 remained disease free for 2 years following
tumour regression but at the age of 5 years, a tumour
biopsy confirmed recurrence of DFT1. Serum antibodies per-
sisted in TD3 at this time and tumour-infiltrating MHC-II
positive cells and CD3 positive T lymphocytes were present
in the biopsy. TD4 remained disease free for 3 years to the
age of 6, beyond which it was not retrapped (6 years is
considered the maximum lifespan for a wild devil).
Tumour regression for TD5 and TD6 was not observed;
however, their tumour samples showed interesting features.
At the time of TD5’s seroconversion, the biopsy had
tumour infiltration of MHC-II and CD3 positive cells
(figure 2). TD6 had tumour FNAs and serum collected
when first trapped and again three months later. Cells from
the initial FNA were periaxin positive and faintly positivefor b2m (figure 2j,k); however, three months later, coinciding
with seroconversion, the periaxin positive cells were strongly
positive for b2m, indicating MHC-I expression by the DFT1
cells (figure 2l). Neither TD5 nor TD6 was retrapped follow-
ing seroconversion. In contrast with TD3, TD5 and TD6, the
tumour samples from devils without serum antibody did
not show significant tumour infiltration of immune cells or
b2m staining.4. Discussion
The immune escape mechanisms of DFT1 play a significant
role in its successful transmission and tumour development.
While anti-DFT1 immune responses have been induced in
captive devils by immunizing with killed DFT1 cell prep-
arations [10], no convincing evidence for immune responses
against DFT1 have previously been identified in wild
devils. Here we report the first evidence, we believe, of
anti-DFT1 immune responses occurring in wild Tasmanian
devils exposed to DFT1.
The serum antibodies directed against IFN-g treated DFT1
cells (MHC-Iþve) found in six devils may have resulted from an
initial immune response against the primary tumour and sub-
sequent IFN-g release. This may have upregulated MHC-I
expression on the DFT1 cells, resulting in an immune response
against these modified cells. Our results indicate that this
response is initiated by infiltrating T lymphocytes, which,
although rare, have been documented in at least one case of
DFT1 and associated with tumour cell surface expression of
MHC-I [7]. What caused the initial immune response is not
clear. However, the increase in MHC-I expression on DFT1
cells potentially provided a mechanism for T-cell-mediated
killing of tumour cells and ultimately tumour stabilization or
regression. Antibody production, in the form of IgG, provides
confirmatory evidence that an anti-DFT1 immune response
had been generated. It was not possible to accurately measure
IgM levels via flow cytometry to determine if IgM/IgG ratios
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Figure 2. Evidence for immune cell infiltration of DFT1 or MHC-I expression of DFT1 cells. (a– i) IHC staining of DFT1 tumour biopsies. Top and middle rows taken at
20 magnification, scale bar indicates 100 mm. Bottom row taken at 100 magnification, scale bar indicates 20 mm. Positive cells for each marker are brown;
haematoxylin (blue) is the counter stain. (a,d,g) periaxin, marker for DFT1 cells; (b,e,h) CD3, marker for T lymphocytes; (c,f,i) MHC-II, marker for antigen-presenting
cells; (a– c) typical DFT1 biopsy with no evidence of immune response; (d– f ) tumour biopsy from TD5 showing infiltration of CD3 and MHC-II positive cells
throughout the tumour; (g– i) tumour biopsy from TD5 showing immune cells infiltrating DFT1 cell clusters. ( j– l ) ICC of DFT1 cells with periaxin (red), and
b2m (green) to identify MHC-I surface expression: ( j ) DFT1 cells from culture; (k) DFT1 FNA from TD6 collected in November 2013; (l ) DFT1 FNA from TD6 collected
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dependent cell-mediated cytotoxicity. Although there are sig-
nificant differences between CTVT and DFT1, they share
characteristics of transmissibility and MHC-I downregulation.
Indeed the development of IgG antibodies against DFT1 cells
may parallel what is believed to occur in CTVT cases: after
the canine tumour has established there are increased numbers
ofMHC-Iþve CTVT cells discernible by immunohistochemistry
and immunocytochemistry, and thedevelopment of serum IgG
antibodies against CTVT cells occurs [8,9]. The experimentally
inducedCTVTs tend to regress [8],whereas the naturallyoccur-
ring tumours seem to remain in equilibrium as locally invasive
tumours with metastases being uncommon [14]. It is probable
that this equilibrium or regression occurs as a result of the
increased MHC-I expression of the tumour cells. Theconsecutive tumour FNAs taken from TD6 showed increased
intensity of b2m surface staining indicative of increased
MHC-I expression on the DFT1 cells. Upregulation of MHC-I,
along with seroconversion occurring at that time, indicates
that DFT1 and CTVT may share additional characteristics of
disease progression.
While there has been no observed reduction in the demo-
graphic effect of DFT1 in the local population of this study,
this evidence indicates that DFT1 does not always escape
detection by the immune system, and death may not be the
inevitable outcome of infection. The naturally occurring
immune responses against DFT1 may enable identification
of significant tumour antigens and thus advance DFT1 vac-
cine development. If there is a heritable component to the
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increased survival and, therefore, lifetime reproductive
output leading to increased representation of these devil
lineages and increased survival of wild populations.
In summary, we have demonstrated a naturally occurring
immune response against DFT1 in this population of wild
devils. Our findings highlight the value of monitoring
disease at the individual level where ongoing microevolu-
tionary changes can be detected and permit evaluation of
their impact on the disease trajectory and epidemic outcome
at a population level.
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